Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Bayer : Halts Phase 3 Study on New Xarelto Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 08:44am CET
   By Sarah Sloat 

Bayer AG (>> Bayer) said late Thursday it halted a phase 3 study for the use of blood-thinning drug Xarelto because it didn't show improved efficacy compared with another treatment using aspirin.

The Navigate Esus study was testing Xarelto for the secondary prevention of strokes and systemic embolism in patients who recently had an embolic stroke of undetermined source.

Researchers stopped the trial early because the Xarelto and aspirin arms of the study showed comparable efficacy, and there was little chance of an overall benefit if it were completed, the German pharmaceutical and chemicals company said.

"While bleeding rates were low overall, an increase in bleeding was observed in the [Xarelto] arm compared to the low-dose aspirin arm," Bayer said.

Xarelto, also known as rivaroxaban, is a prescription anticoagulant which been approved for seven indications. The drug contributed just over 2.9 billion euros ($3.4 billion) in sales to Bayer's pharmaceutical division last year.

The drug was developed jointly by Bayer and Janssen Pharmaceuticals, a unit of Johnson & Johnson (>> Johnson & Johnson). It is marketed outside the U.S. by Bayer and within the U.S. by Janssen.

Write to Sarah Sloat at [email protected]

Stocks mentioned in the article : Bayer, Johnson & Johnson
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.47% 133.68 Delayed Quote.-4.77%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
03/15BAYER : Researchers Submit Patent Application, "Antibody and Protein Formulation..
03/15Bayer faces U.S. antitrust hurdles for Monsanto merger - Bloomberg
03/15BAYER : Annual Preventative Maintenance and Service Agreement for a MedRad- (Bay..
03/14KNOW ABOUT PRIMARY CILIARY DYSKINESI : Key players profiled in this report Astra..
03/14BAYER : reports progress in talks with Russia over Monsanto deal
03/13LIVESTOCK HIGHLIGHTS : Top Stories of the Day
03/13China conditionally approves Bayer's acquisition of Monsanto
03/13China conditionally approves Bayer's acquisition of Monsanto
03/13BAYER : China Approves Bayer's Plan to Buy Monsanto With Conditions
03/08BAYER CROPSCIENCE : Managing risk
More news
News from SeekingAlpha
03/15Monsanto -5% as Bayer tie-up reportedly faces more antitrust hurdles 
03/14REUTERS : Bayer sees progress in talks with Russia over Monsanto deal 
03/13ROAD TO FINANCIAL INDEPENDENCE : My February 88-Stock Portfolio Review With Big .. 
03/13China conditionally approves Bayer takeover of Monsanto 
03/113 THINGS IN BIOTECH, MARCH 10 : Merck In MS, Bayer's Essure Scrutinized, Tocagen.. 
Financials (€)
Sales 2018 35 876 M
EBIT 2018 7 338 M
Net income 2018 4 846 M
Debt 2018 5 116 M
Yield 2018 2,96%
P/E ratio 2018 16,69
P/E ratio 2019 14,91
EV / Sales 2018 2,33x
EV / Sales 2019 2,24x
Capitalization 78 428 M
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 119 €
Spread / Average Target 25%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-8.13%96 348
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965